🇺🇸 FDA
Pipeline program

Sparsentan

TVTX-RE021-426

Approved small_molecule active

Quick answer

Sparsentan for Proteinuria is a Approved program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Travere Therapeutics
Indication
Proteinuria
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials